Abstract
This study investigated the effect of verapamil metabolites on R- and S-verapamil protein binding in plasma samples collected from subjects prior to rac-verapamil dosing and following single dose and steady state rac-verapamil dosing. In vitro studies of the effects of norverapamil, D617 and D620 on R- and S-verapamil protein binding were also performed. Protein binding of R- and S-verapamil was unchanged following single and multiple doses of rac-verapamil as compared with protein binding in pre-dose samples. In vitro, norverapamil had no effect on R- and S-verapamil protein binding up to 1000 ng ml-1. Norverapamil 5000 ng ml-1 caused a 30% increase in free fraction of both R- and S-verapamil. D617 and D620 concentrations up to 5000 ng ml-1 had no effect on R- and S-verapamil protein binding. We conclude the metabolites of verapamil have no clinically significant effect on R- and S-verapamil protein binding.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Echizen H., Vogelgesang B., Eichelbaum M. Effects of d,l-verapamil on atrioventricular conduction in relation to its stereoselective first-pass metabolism. Clin Pharmacol Ther. 1985 Jul;38(1):71–76. doi: 10.1038/clpt.1985.137. [DOI] [PubMed] [Google Scholar]
- Gross A. S., Heuer B., Eichelbaum M. Stereoselective protein binding of verapamil enantiomers. Biochem Pharmacol. 1988 Dec 15;37(24):4623–4627. doi: 10.1016/0006-2952(88)90330-9. [DOI] [PubMed] [Google Scholar]
- Huang J. D. Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis. J Pharm Sci. 1983 Nov;72(11):1368–1369. doi: 10.1002/jps.2600721137. [DOI] [PubMed] [Google Scholar]
- Keefe D. L., Yee Y. G., Kates R. E. Verapamil protein binding in patients and in normal subjects. Clin Pharmacol Ther. 1981 Jan;29(1):21–26. doi: 10.1038/clpt.1981.4. [DOI] [PubMed] [Google Scholar]
- Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer. 1993 Oct;68(4):813–818. doi: 10.1038/bjc.1993.433. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vogelgesang B., Echizen H., Schmidt E., Eichelbaum M. Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique. Br J Clin Pharmacol. 1984 Nov;18(5):733–740. doi: 10.1111/j.1365-2125.1984.tb02536.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Yong C. L., Kunka R. L., Bates T. R. Factors affecting the plasma protein binding of verapamil and norverapamil in man. Res Commun Chem Pathol Pharmacol. 1980 Nov;30(2):329–339. [PubMed] [Google Scholar]